Selective inhibition of ASIC1a confers functional and morphological neuroprotection following traumatic spinal cord injury [version 2; referees: 2 approved]

Liam M. Koehn¹, Natassya M. Noor¹, Qing Dong¹, Sing-Yan Er², Lachlan D. Rash²,³, Glenn F. King², Katarzyna M. Dziegielewska¹, Norman R. Saunders¹, Mark D. Habgood¹

¹Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Australia
²Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Australia
³School of Biomedical Sciences, The University of Queensland, St. Lucia, Australia

Abstract
Tissue loss after spinal trauma is biphasic, with initial mechanical/haemorrhagic damage at the time of impact being followed by gradual secondary expansion into adjacent, previously unaffected tissue. Limiting the extent of this secondary expansion of tissue damage has the potential to preserve greater residual spinal cord function in patients. The acute tissue hypoxia resulting from spinal cord injury (SCI) activates acid-sensing ion channel 1a (ASIC1a). We surmised that antagonism of this channel should provide neuroprotection and functional preservation after SCI. We show that systemic administration of the spider-venom peptide PcTx1, a selective inhibitor of ASIC1a, improves locomotor function in adult Sprague Dawley rats after thoracic SCI. The degree of functional improvement correlated with the degree of tissue preservation in descending white matter tracts involved in hind limb locomotor function. Transcriptomic analysis suggests that PcTx1-induced preservation of spinal cord tissue does not result from a reduction in apoptosis, with no evidence of down-regulation of key genes involved in either the intrinsic or extrinsic apoptotic pathways. We also demonstrate that trauma-induced disruption of blood-spinal cord barrier function persists for at least 4 days post-injury for compounds up to 10 kDa in size, whereas barrier function is restored for larger molecules within a few hours. This temporary loss of barrier function provides a "treatment window" through which systemically administered drugs have unrestricted access to spinal tissue in and around the sites of trauma. Taken together, our data provide evidence to support the use of ASIC1a inhibitors as a therapeutic treatment for SCI. This study also emphasizes the importance of objectively grading the functional severity of initial injuries (even when using standardized impacts) and we describe a simple scoring system based on hind limb function that could be adopted in future studies.
Introduction

Traumatic spinal cord injuries (SCIs) are devastating for patients due to the sudden and irreversible loss of motor, sensory and autonomic functions at and below the level of injury (Hou & Rachedevs, 2014; Scivoletto et al., 2014). It is estimated that as many as 500,000 people suffer a spinal cord injury every year (World Health Organization, 2013) with each incident requiring lifelong medical care amounting to approximately $USD 3.5–6.8 million over the course of a lifetime. There are currently no effective pharmacological treatments available to reverse trauma-induced tissue loss and restore lost functions for patients. The prevalence of this devastating and currently untreatable injury makes it a prominent issue for biomedical research.

The extent of functional losses following a SCI is largely determined by two factors: (i) the level at which the injury occurs (tetraplegia with cervical injuries or paraplegia with thoracic and lumbar injuries) and (ii) the extent of tissue damage at the lesion site (complete or incomplete). The pathology of tissue damage after SCI occurs in a biphasic manner. Initial physical (primary) damage at the time of injury due to mechanical compression, stretching and shearing of tissue is typically localised to the central grey matter (Ek et al., 2010; Schwab et al., 2006; Tator & Fehlings, 1991; Wolman, 1965). This is followed by a period of ‘secondary’ expansion of the lesion into surrounding undamaged tissue (the peri-injury zone) over hours to days after injury (Ek et al., 2012; Zhang et al., 2012). Our previous work has shown that secondary loss of grey matter is mostly complete within the first 24 h, whereas secondary loss of surrounding white matter tracts continues for several days post-injury (Ek et al., 2010; Ek et al., 2012). Since this secondary loss is tissue that survived the initial impact, it is potentially salvageable if suitable neuroprotective treatments can be identified, administered and gain access to the injury site before it has become irreversibly damaged.

Primary tissue loss is characterized by extensive necrotic cell death similar to haemorrhagic stroke. Indeed, magnetic resonance imaging (MRI) studies of human SCIs have shown positive correlations between the extent of spinal haemorrhage/oedema and the extent of permanent functional deficits in patients (Boldin et al., 2006; Flanders et al., 1999; Parashari et al., 2011). In contrast, secondary tissue loss largely occurs by apoptotic cell death (Byrnes et al., 2007; Yong et al., 1998). The mechanisms underlying this secondary apoptotic period are thought to involve structural, cellular, biochemical and vascular changes in the region surrounding the primary injury site (reviewed in Schwartz & Fehlings, 2002 and Zhang et al., 2012). Vascular compromise appears to play a prominent role, with evidence from animal and human studies showing marked reductions in blood flow at the site of the spinal injury and in adjacent proximal regions (Rivlin & Tator, 1978; Soubeyrand et al., 2013; Tei et al., 2005). Compression and rupture of central grey matter blood vessels not only disrupts blood supply to the central grey matter, but also to the deeper layers of surrounding white matter that are supplied by these damaged central vessels (Koyanagi et al., 1993; Losey & Anthony, 2014; Losey et al., 2014; Tator & Koyanagi, 1997). The resulting hyperfusion creates a zone of acute tissue hypoxia and ischaemia surrounding the physical lesion, commonly referred to as an ischemic penumbra. Trauma-induced ischaemia, and the consequent hypoxia, are widely regarded as central initiators of the cascade of events underlying secondary tissue damage after SCI (Amar & Levy, 1999; Rowland et al., 2008; Tator & Fehlings, 1991; Tator & Koyanagi, 1997) and have also been shown to promote apoptosis in rats (Linnik et al., 1993) and piglets (Mehmet et al., 1994).

The mechanisms by which hypoxia/ischaemia induce cell death are not clearly understood. Acute tissue acidosis in regions of hypoperfusion is sufficient to activate acid-sensing ion channel 1a (ASIC1a), a proton-gated ion channel that mediates influx of sodium and calcium into cells (Yermolaieva et al., 2004). Preventing ASIC1a activation with intravenous HCO₃⁻ reduced tissue loss and functional deficits in a traumatic brain injury model (Yin et al., 2013), and genetic ablation or pharmacological inhibition of ASIC1a reduces neuronal injury following ischemic stroke (Xiong et al., 2004; Yin et al., 2013). It has been proposed that excessive Ca²⁺ influx via ASIC1a may induce mitochondrial dysfunction (Friese et al., 2007; Sherwood et al., 2011) and promote activation of intrinsic apoptotic pathways including alterations in BAX/BCL2 ratios and activation of caspase-3 (Smaili et al., 2003).

ASIC1a is expressed by most neurons in the central and peripheral nervous systems and multiple studies have confirmed expression on spinal cord neurons (Baron et al., 2008; Wu et al., 2004). ASIC1a expression on oligodendrocyte lineage cells has also been reported, implicating this channel in both grey and white matter damage (Feldman et al., 2008).

Psalmotoxin (PcTx1) is a 40-residue, 4.6 kDa peptide from venom of the Trinidad chevron tarantula, Psalmopoeus cambridgei (Escoubas et al., 2000). PcTx1 is the most potent described inhibitor of ASIC1a with an IC₅₀ of ~1 nM, and it has minimal effect on other ASIC subtypes (Escoubas et al., 2000). In addition to PcTx1, ASIC1a is inhibited to a lesser extent by the diuretic amiloride (IC₅₀ ~10 μM; (Gründler & Chen, 2010), non-steroidal anti-inflammatory drugs such as flurbiprofen (IC₅₀ ~350 μM; (Voilley et al., 2001)) and alkaloids such as sinomenine (IC₅₀ ~0.27 μM; (Wu et al., 2011)). While all of these non-selective ASIC blockers are neuroprotective in rodent stroke models (Mishra et al., 2011; Wu et al., 2011; Xiong et al., 2004; Zheng et al., 2007), PcTx1 provides the best level of neuroprotection (Pignataro et al., 2007; Xiong et al., 2004; Xiong et al., 2006; Xiong et al., 2008). Intracerebroventricular administration of recombinant PcTx1 at 2 h post-stroke was found to reduce infarct volume by ~70% in a rat model of middle cerebral artery occlusion, which...
correlated with improvements in neurological score and motor function as well as preservation of neuronal architecture (McCarthy et al., 2015). There has been one report of neuroprotection in a SCI model using intrathecal administration of a *P. cambridgei* venom extract containing PcTx1 (Hu et al., 2011). Unfortunately, PcTx1 constitutes only ~0.4% of the protein content of *P. cambridgei* venom (McCarthy et al., 2015), which contains hundreds of other bioactive peptides that act on a range of ligand and voltage-gated ion channels. Thus, the results obtained with crude venom extracts cannot be taken as definitive evidence that ASIC1a antagonism by PcTx1 is neuroprotective in SCI.

Here we show conclusively that pure recombinant PcTx1 delivered systemically is neuroprotective after SCI in rats, reducing the extent of secondary tissue loss and improving locomotor function. In addition, transcriptomic analysis revealed a significant effect of initial lesion size on the differential expression of genes in different regions of the spinal cord in relation to the injury centre. Inflammatory associated genes predominated in the rostral penumbra, whereas genes associated with blood vessels (e.g. actin and myosin) dominated at the lesion centre, possibly indicative of vascular remodelling. Together the transcriptomic data suggest that the mechanism of action by which PcTx1 confers neuroprotection involves modification of inflammatory and vascular responses to SCI.

**Materials and methods**

**Production of recombinant PcTx1**

Recombinant PcTx1 was produced as described previously via expression in the periplasm of *Escherichia coli* (Saez et al., 2011; Saez et al., 2015). Briefly, recombinant His<sub>6</sub>-MBP-PcTx1 fusion protein was isolated from cell lysates by passage over Ni-NTA Superflow resin (QIAGEN) and the His<sub>6</sub>-MBP tag was then removed by cleavage of the fusion protein with tobacco etch virus (TEV) protease. The released recombinant PcTx1 containing a non-native N-terminal serine to facilitate TEV cleavage (Saez et al., 2011) was isolated to >95% purity using reverse-phase HPLC. The isolated recombinant PcTx1 peptide is equipotent with native PcTx1 (Saez et al., 2011).

**Animals**

All procedures involving animals were approved by The University of Melbourne Animal Ethics Committee (Approval number: 1212637) and conducted in compliance with Australian National Health and Medical Research guidelines. Adult female Sprague Dawley rats (weight range 205–285 g) were supplied by The University of Melbourne Biological Research Facility and housed in horizontal ladder of 76 cylindrical metal bars (3 mm thick, 7 mm vertebral laminecetomy. The vertebral column was then stabilized in a stereotaxic frame with clamps attached to the T9 and T11 dorsal vertebral spines. A single contusion injury was applied to the dorsal surface of the exposed spinal cord using a computer-controlled impactor (Ek et al., 2010; Ek et al., 2012) using impact parameters previously determined to produce moderate incomplete spinal cord lesions mostly confined to the central grey matter.

**Treatment protocols**

Mini-osmotic pumps (Alzet®1003D, BioScientific, Australia) were filled with a solution of PcTx1 in sterile saline (1.03 mg/ml) and primed for 12–24 h at 37°C in phosphate buffered saline (PBS). Immediately after the contusion injury, animals assigned to the PcTx1-treated group (n=12) received an intraperitoneal loading dose of PcTx1 (12.5 μg/kg) and a mini-osmotic pump containing PcTx1 was implanted subcutaneously between the shoulder blades and the wound site closed with several layers of sutures. The role of the pump was to slowly and steadily release PcTx1 (1.08 μg/h) subcutaneously to compensate for estimated renal and tissue losses of PcTx1 over the first 48 h period. Saline-treated animals (n=16) received an equivalent intraperitoneal injection of saline, but no osmotic pump was implanted. Uninjured, untreated rats (n=6) were included as reference controls.

**Assessing and grading the severity of the initial injuries**

An inherent feature of all spinal contusion models is inter-animal variations in the size of the initial spinal cord lesions produced. Whilst the impactor device used in this study delivers standardized and highly reproducible impacts (Ek et al., 2010; Ek et al., 2012), differences in the number and location of ruptured blood vessels will result in differences in the extent of tissue ischaemia, hypoxia and ultimately tissue loss. Accordingly, the functional severity of the initial injuries in each animal was assessed upon full recovery from anaesthesia and again at 24 h post-injury using a simplified injury severity (SIS) scale ranging from 0 (normal locomotion) to 3 (complete flaccid hind limb paralysis; see Table 2). This scale was independently developed, but the assessment criteria are similar to those described by Herrmann et al. (2008) and Anderson et al. (2016), and shown in Table 2. Each hind limb was assessed separately and an average of both hind limbs recorded. The criteria for inclusion in the study were an SIS score >1 and <3. Only one saline-treated animal fell outside this range (1.0) and was excluded. From this point on the study was blinded, ensuring that the researchers performing subsequent analyses (functional, morphological and transcriptomic) were not aware of which SCI treatment group the rats belonged to. Animal identities were decoded at the end of the data collection.

**Functional testing**

A number of commonly used functional tests were conducted at 6 weeks post-injury (±0.5 weeks) by 2–3 independent observers. All observers were blinded to animal identity and treatment group during the testing. Open field locomotion and gait were assessed using the Basso, Beattie and Bresnahan (BBB) scale (Basso et al., 1995) as animals walked across a flat surface. Complex coordinated motor function was assessed by the animals’ ability to traverse a horizontal ladder of 76 cylindrical metal bars (3 mm thick, 7 mm
Histological analysis

At the end of each experimental period (24 h or 6 weeks post-injury) injured animals (together with age-matched controls) were terminally anaesthetized with an overdose of inhaled isoflurane (Lyppard Australia), the chest cavity opened and transcardially perfused with 50 ml heparinised (5 IU/ml) PBS (80 ml/min/kg) followed by 150 ml of 4% paraformaldehyde solution. The spinal cords were dissected out and a 10 mm segment centred on and enclosing the injury site removed and post-fixed overnight in Bouin’s fixative (Sigma-Aldrich, Australia). Cords were dehydrated through increasing concentrations of ethanol then cleared overnight in chloroform before being mounted in paraffin wax (Paramat, VWR International). The embedded cord segments were serially sectioned in the transverse plane (Leica RM2125RT microtome, 5 μm thick sections) and sequential ribbons of 10 sections mounted on numbered glass slides. Slides were dewaxed, cleared through histolene (Fronine, Australia) and hydrated through decreasing concentrations of ethanol. Standard procedures were used for Hematoxylin and Eosin (H&E; Sigma-Aldrich) and Luxol Fast Blue (LFB; Gurr UK) staining. For immunohistochemical stains, peroxidase and protein blockers were applied (DAKO, 2 h each) before overnight incubation with primary antibodies (1:500 monoclonal mouse anti-CNPase, Sigma-Aldrich C5922 or 1:500 polyclonal rabbit anti-Fox3, abcam Ab104225) at 4°C. Secondary antibodies (1:100 polyclonal horse anti-mouse biotinylated, VECTORS BA2001 or 1:200 polyclonal swine anti-rabbit, DAKO Z0196) were administered and incubated for 1.5 h before application of either ABC kit (DAKO) or polyclonal rabbit PAP (Sigma-Aldrich P1291) complexes respectively. For both methods the final reaction product was developed with the DAB kit (DAKO).

Quantification of immunocytochemical staining

Tissue sections were viewed and photographed (with scale bars) using a light-microscope (Olympus BX50 fitted with a DP60 digital camera). Areas of positive stained tissue were measured using ImageJ (Abramoff et al., 2004). The embedded scale bar in each image was used to calibrate the pixel-to-distance ratio, the perimeter of positive staining outlined manually and the enclosed area measured. In sections containing a central cystic cavity, the area of the cystic cavity was subtracted from the total cord cross-sectional area of the section to determine the area of remaining tissue.

Specific tissue regions containing some of the white matter tracts involved in hind limb motor function were outlined and measured separately. The dorsal column corticospinal tract (dcCST) located at the base of the dorsal column was not measured because it was no longer present at 6 weeks post-SCI. The rubrospinal tracts (RST) and dorsolateral corticospinal tracts (dCST) are located in the dorsolateral white matter (dLWM) just below the dorsal horns. Preserved dLWM area was defined as positive stained tissue bounded by the lower edge of the dorsal horn at the dorsal extremity and a line drawn at right angles to the pial surface of the cord at a point located 0.3 mm down the outer circumference at the ventral extremity (shown in Figure 1). For each cord, the sum of the left and right dLWM preserved areas was recorded.

The ventro-medial white matter (vWM) showed substantial tissue damage (“holes”) in all injured animals and thus simply outlining the perimeter of positive staining did not provide an accurate assessment of the true extent of tissue preservation. To estimate the actual area of positive tissue staining, a 0.4 mm and 0.6 mm rectangle was placed over the ventromedial region centred on and enclosing the sulcal fissure (Figure 1). The number of pixels within the rectangle that were above a baseline threshold colour (the minimum colour considered to reflect positive staining) was recorded and the corresponding area calculated using the known pixel-to-distance ratio for the image (i.e. the embedded scale bar).

All dLWM and vWM measurements were recorded as an average of two sections (5 to 10 sections/25–50 μm apart) from the centre of the injury site. The centre of the injury in each cord segment (section with the smallest preserved tissue area) was determined from serial reconstructions of tissue area in H&E sections equally spaced along the entire length of the cord segment. All LFB and CNPase dLWM and vWM measurements were made within ± 450 μm of the lesion centre (i.e. ± 9 slides).

To count the number of FOX3-positive grey matter neurons, images of the stained spinal sections were manually counted using the count tool in Photoshop (Adobe Systems). This places a sequentially numbered spot on top of each immunopositive cell. The image together with numbered spots is saved and compared with the same image counted by the other assessors.

Statistical analyses

The functional performance of PcTx1-treated and saline-treated animals was compared using two-way analysis of covariance (ANCOVA, Prism v6, Graphpad, San Diego, USA). This method uses the General Linear Model approach and fits least
squares linear regression lines to the raw data for individual animals then compares the slopes (correlations) of the regression lines. If the slopes are found to be equal, the intercepts (elevations) are then compared. Differences in the initial injury severity between animals within each group introduces a covariate that makes a substantial contribution to the total observed variance in each treatment group. The presence of this covariate negates the use of simple parametric testing such as ANOVA and Student’s t-Test.

Blood-spinal cord barrier integrity
Blood-spinal cord barrier (BSCB) function at the lesion site was assessed between 2 h and 7 days post-SCI for different size permeability tracers \( (n=2 \text{ per tracer and time point}) \) in a separate series of 38 untreated, injured rats. At 30 minutes prior to the time of BSCB assessment, animals were anaesthetised with urethane (1–1.5 g/kg, i.p.) and a femoral vein injection (100 μl) containing one of the following permeability tracers dissolved in sterile saline was administered: 286 Da biotin ethylene diamine (BED, A-1593 Life Technologies Australia), 3 kDa biotin-dextran-amine (BDA, D3308, Life Technologies Australia), 10 kDa dextran rhodamine B (DRB, D-1824, Life Technologies Australia), 44kDa horseradish peroxidase (HRP, P-8375 Sigma-Aldrich, Australia) or 70 kDa dextran fluorescein (DF-70kDa, A-1823, Life Technologies Australia). After 20 minutes of circulation time the animals were administered an overdose of anaesthetic (inhaled isoflurane). A 10 mm segment of spinal cord enclosing the injury site was removed post-mortem and immersion-fixed in 4% paraformaldehyde. For animals injected with HRP or BED, the cord segments were embedded in 4% agar, serially sectioned (70 μm thickness) in a vibrating microtome (Leica VT1000S) and stained with DAB (D-5905, Sigma-Aldrich, Australia). For animals injected with the dextran tracers, the spinal segments were embedded in paraffin wax, serially sectioned in the transverse plane at 5 μm thickness and mounted on glass slides (10 sequential sections per slide). Sections approximately 0.5 mm apart along the entire length of the cord segment were inspected under fluorescence microscopy. BSCB function was interpreted as disrupted where tracer was visible outside blood vessels within the spinal tissue and interpreted as intact where the tracer was completely confined to the lumen of blood vessels.

Transcriptomics: RNASeq (Illumina platform)
PcTx1 \( (n=3) \) and saline treated animals \( (n=3) \) were sacrificed 24 h after injury (overdose of inhaled isoflurane), the thoracic region of the spinal cord was removed under RNase-free conditions and 3 mm long segments collected from the injury centre, the adjacent cord rostral to the injury centre and the adjacent cord caudal to the injury centre. Each 3 mm segment was placed into separate cryovials containing RNA-later solution (Life Technologies Australia) for 2 h before being snap frozen by placing the cryovials into liquid nitrogen. Total mRNA in each sample was extracted using commercial kits (RNeasy, Qiagen) and stored at -80°C. Transcriptome datasets were generated using RNAseq analysis.
Analysis of transcript variance revealed effects of initial lesion severity (SIS scores) between individual animals within each treatment group (see Transcriptomic analysis below). Accordingly, subsequent analysis was made comparing only datasets from animals with similar sized initial injury severities.

FC values were calculated from FKPM (fragments per kilobase of transcript per million mapped reads) values in the PcTx1-treated vs saline-treated groups for animals with similar SIS scores. Positive fold changes indicate that the genetic transcript was present in a higher proportion in PcTx1-treated animals in that part of the cord compared to saline-treated animals, with negative values indicating lower proportions in PcTx1-treated animals. Gene set testing was conducted to identify enriched pathways using the Gene ontology 'Panther' classification system (Mi et al., 2013).

Results
Assessment of the severity of the initial injury
Despite the fact that all animals received the same mechanical impact to the spinal cord (2 mm diameter tip, 0.30 m/s ± 0.04 S.D. impact velocity, 1.44 mm ± 0.01 S.D. penetration depth, 0.997s ± 0.004 S.D. compression time), the resulting initial injury severity (SIS) scores ranged from 1.50 to 2.75 (Table 1). This reflects the inherent variability of spinal tissue injuries even when conducted using a well-validated impactor (Ek et al., 2010) operated by an experienced experimenter. There was no correlation between any of the impact parameters and SIS scores (data not shown). There was also no significant difference between the average SIS scores of the PcTx1-treated and saline-treated groups (Table 1). However, within each treatment group there was a range of initial injury severities and for this reason each animal’s results were plotted against their initial SIS score for analyses.

Table 2. A simplified injury severity (SIS) scale based on simple observable criteria for assessing initial gross locomotor functional deficits soon after spinal cord injury in rats. Animals are first assessed by the presence (scores 0–1.5) or absence (scores 2–3) of weight supported hind limb stepping. Those exhibiting weight support are then graded on the basis of the visual severity of any gait abnormality (none, slight or gross). Those without weight support are graded on the basis of how many joints (hip, knee, ankle) they are able to voluntarily flex/extend (none, one or more than 1) when restrained by holding the tail and lifting the hind quarters gently up and lowering back down. Each hindlimb is assessed independently and the average of both recorded. The most equivalent grades on the scale used by Herrmann et al. (2008) and Anderson et al. (2016) are shown on the right.

| Simplified Injury Severity (SIS) Grading Scale |  |
| Weight support | Stepping pattern | Extend & flex joints | SIS Score | Equivalent Herrmann Grading |
|---|---|---|---|---|
| YES | Normal | all | 0 | hindlimb function essentially normal |
| Slight abnormality | all | 1 | hindlimb used for weight support and stepping, but obvious disability |
| Gross abnormality | all | 1.5 | hindlimb assisted in occasional weight support and plantar placement, but not in stepping |
| NO | No stepping | two or more | 2 | hindlimb movements obvious, but did not assist in weight support or stepping |
| | one | 2.5 | little voluntary hindlimb movement |
| | none | 3 | no voluntary hindlimb movement |

Table 1. Comparisons of mean initial injury severity (SIS scores) in the PcTx1-treated and saline-treated groups of animals (assessments made during the first 24 h post-SCI). All animals received the same mechanical impact to the exposed lower thoracic (T10) spinal cord.

| Initial Injury Severity Scores | Saline-treated | PcTx1-treated | ANOVA (oneway) |
|---|---|---|---|
| SCI + 24 hours | mean ± s.d. | 2.11 ± 0.50 | 2.31 ± 0.40 | p = 0.44 |
| range | 1.50 – 2.75 | 1.75 – 2.75 |
| n | 7 | 6 |
| SCI + 6 weeks | mean ± s.d. | 2.00 ± 0.44 | 2.23 ± 0.37 | p = 0.31 |
| range | 1.50 – 2.75 | 1.75 – 2.75 |
| n | 10 | 6 |
Functional performance at 6 weeks post-injury

At 6 weeks post-injury, there was an inverse correlation between initial injury severity (SIS) scores and residual hind limb function (BBB gait scores, Figure 2a). Over the entire range of initial injury severities, PcTx1-treated animals scored higher on the BBB scale than saline-treated rats. Linear regression and ANCOVA revealed that the data were best described by two separate lines having the same slope, but with the PcTx1-treated group having a significantly higher elevation compared to the saline-treated group ($F_{1,9}=16.1324$, $p=0.003$). Uninjured control rats (diamond symbols in Figure 2a, $n=4$) all scored 21 on the BBB scale.

Figure 2b shows the correlation between the initial SIS scores for individual rats and their average number of hind limb food faults on the horizontal ladder task (average from three repeat attempts). For a given SIS score, PcTx1-treated rats tended to make fewer hind limb errors than saline-treated animals ($n=6$ per group). No significant correlation was observed between SIS scores and foot faults. Control rats ($n=4$) made no hind limb errors along the ladder. There was no significant difference between the two treatment groups on the tapered beam task (Figure 2c) and no correlation between initial SIS scores and average foot faults (from six attempts) on the tapered beam (not shown).

In the swimming test, all PcTx1- and saline-treated rats were able to kick their hind limbs in a coordinated manner indicating the presence of some supraspinal control of hind limb function. There was no observable differences between the two treatment groups in the pattern and style of swimming.

 Preservation of individual white matter tracts at 6 weeks post-injury

Analysis of FOX3 immunopositive neurons, total cross-sectional tissue area (as shown by H&E staining) or general cross-sectional white matter area (as shown by CNPase and LFB staining) did not show any significant differences between PcTx1-treated and saline-treated rats at any point along the spinal cord at 6 weeks post-injury. Thus an in-depth analysis of regions of locomotor importance at the injury centre was conducted.

For a white matter tract in the spinal cord to be functional it requires an uninterrupted connection between the brain nuclei from which the tract axons originate and synaptic connections further down the spinal cord. Thus only the tracts that run all the way through the injury centre would have functional significance for hind limb locomotion. The injury centre was determined by plotting the H&E stained area along the cord (Figure 3) and selecting the point of the least remaining tissue. In the rodent spinal cord, supraspinal motor fibres descend in a number of areas of the cord. The main corticospinal tracts run in the dorsal column (dCST) and the dorsolateral white matter (dlCST) (Steward et al., 2004). Rubrospinal and reticulospinal tracts are also thought to be involved in hind limb locomotion (Watson & Harrison, 2012). In this study, the dCST was completely destroyed and no longer present at 6 weeks post-injury in all rats (See Figure 1). The area of LFB staining in the ventromedial white matter (vmWM) at the injury centre was highly variable and showed no difference between treatment groups. There was, however, a noticeable difference in

Figure 2. Effect of PcTx1 treatment on hind limb function at 6 weeks after SCI. Locomotor functional data are plotted against the initial injury severity (SIS scores): (a) BBB functional scores, (b) horizontal ladder and (c) tapered beam. Each data point represents an individual animal. PcTx1-treated (blue circles), saline-treated (red open circles) and uninjured controls (grey diamonds). Lines in (a) were fitted by least squares linear regression. The datasets in (a) were best described by two separate lines with the same slope ($-1.9681$), but with a statistically significant difference in elevation ($F_{1,9}=16.1324$, $p=0.003$, ANCOVA). The datasets in (b) and (c) were not significantly different. The shaded areas indicate the 95% confidence intervals around each regression line.
Figure 3. Cross-sectional areas of tissue in serial H&E stained transverse sections along the length of the spinal cord at 6 weeks post-injury. Areas of preserved tissue were calculated as the total cord area minus the area of the central cystic cavity. PcTx1-treated rats (blue lines; \( n = 6 \)) and saline-treated rats (red lines; \( n = 6 \)) are shown. Negative values on the x-axis indicate regions rostral to the injury centre (0) and positive values indicate regions caudal to the injury centre. A visual reconstruction of serial H&E traverse sections corresponding to equivalent points along the graph is shown. The relative size and position of the impactor tip at the time of injury is also indicated.

the appearance of myelin in this region between treatment groups as illustrated in Figure 4.

In PcTx1-treated animals, myelin showed fewer axotomised tracts and a denser staining pattern compared to saline-treated SCI controls (Figure 4). In addition, PcTx1-treated animals had significantly larger areas of preserved dorsolateral white matter (dLWM) compared to saline-treated animals (Figure 5). ANCOVA revealed two separate lines with the same slope best described the data with the PcTx1-treated group having a significantly higher elevation (Figure 5; \( F_{(1,8)} = 12.9908, p = 0.0069 \)). Similar results were obtained from adjacent sections stained with H&E or CNPase (data not shown).

A positive correlation was observed between the preserved area of LFB staining in the dLWM at the injury centre and functional performance assessments using BBB scores (Figure 6a) and the horizontal ladder task (Figure 6b). There was no correlation between LFB area in the dLWM and performance on the beam task (not illustrated). PcTx1-treated rats typically had larger areas of preserved dLWM that correlated with better functional outcomes.

Morphology at 24 h post-injury
Although 6 weeks post-injury is a suitable time-point for long-term functional assessment, it is well after the response to injury has concluded. Thus, analysis was also conducted at an earlier 24 h post-injury time-point, when white matter loss is still continuing (Ek et al., 2010; Ek et al., 2012), to determine the potential mechanisms of PcTx1 neuroprotection.

Assessments of tissue area using H&E and LFB staining could not be accurately performed at this time due to the presence of significant amounts of blood within the cord and the distinction between live and recently dead tissue is not apparent, both of which affect interpretation of staining. The only morphological analyses that were possible to meaningfully conduct were immunocytochemistry for FOX3 and CNPase. No significant differences were observed between PcTx1-treated and saline-treated groups at 24 h post-injury in terms of the average numbers of FOX3 immunopositive neurons at any point along the 10 mm length of cord segment (not illustrated).

Total white matter area as determined by measurements of CNPase positive staining revealed preservation of tissue at the injury centre in PcTx1-treated animals with higher severity injuries (SIS ~2.5, 1.27 mm² and 1.05 mm² in PcTx1-treated versus 0.631 mm² and 0.734 mm² in saline-treated), but not in animals with lower severity injuries (SIS 1.5, 1.38 mm² in PcTx1-treated versus 1.40 mm² in saline-treated). This greater effect of the PcTx1 treatment in animals with more severe injuries was also apparent in the dLWM area measurements (SIS ~2.5, 0.166 mm² and 0.137 mm² in PcTx1-treated versus 0.09 mm² and 0.056 mm² in saline-treated compared to SIS 1.5, 0.143 mm² in PcTx1-treated versus 0.147 mm² in saline-treated). This suggests that PcTx1 treatment was more effective at preserving white matter in animals with more severe injuries at 24 h post-SCI.

Transcriptomic analysis
RNAseq transcriptomic analysis of the spinal cord at 24 h after a contusion injury was performed on PcTx1-treated and saline-treated...
Figure 4. Luxol fast blue (LFB) stained transverse cross-sections from the injury site of an uninjured control (a and b), saline-treated (c and d) and PcTx1-treated (e and f) animals. The outlined areas in (a), (c) and (e) are shown at higher magnification in (b), (d) and (f) to illustrate the preservation of myelin in the ventromedial areas of these cords. Note the increased numbers and sizes of myelin-devoid spaces in the saline-treated cord (d) compared to the PcTx1-treated cord (f). The saline-treated rat (c and d) had an initial simplified injury severity score (SIS) of 1.73 and the PcTx1-treated rat (e and f) had an SIS of 1.9.

Figure 5. Cross-sectional areas of luxol fast blue (LFB) staining of the dorsolateral white matter (dLWM) 6 weeks after injury plotted against each rats’ initial injury severity (SIS score). Saline-treated rats (red open circles; n=6), PcTx1-treated rats (blue circles; n=6) and control rats (grey diamonds; n=2) are shown. All measurements were the average of two sections from the injury centre of each animal. The lines shown were fitted by least squares linear regression. The data were best described by two separate lines with the same slope (-0.0237), but with a statistically significant difference in elevation ($F_{1,8}=12.9908$, $p=0.0069$, ANCOVA). The shaded areas indicate the 95% confidence intervals around each regression line.
animals (n=3 per group) using the Illumina Platform. The SIS scores in the PcTx1-treated animals were: 1.9, 2.5 and 2.75 while in the saline-treated group they were: 2.5, 2.5 and 2.75. Initial differential analysis of the datasets compared the means (n=3) of the PcTx1-treated and saline-treated groups. This highlighted a large number of genes that were significantly differentially expressed (FC>2 or FC<-2): 516 genes rostral to the injury site, 136 genes at the injury centre and 133 genes caudal to the injury site. However, marked inter-animal variance was apparent in the transcript numbers of many of the differentially expressed genes. When transcript counts for the top 50 up- and down-regulated genes were plotted against the initial injury severity (SIS score) for each rat, it was apparent that the severity of the initial injury had a profound effect on gene expression levels (see Figure 7). Accordingly, transcript fold changes were calculated between animals with similar sized injuries. Figure 8 shows gene expression changes between PcTx1-treated and saline-treated animals with 2.5 and 2.75 size initial injury severities. Not only was there a difference in the number of up-regulated and down-regulated genes between the two injury sizes, but there were also marked differences in the panels of differentially expressed genes in different segments of the spinal cord. Table 3 lists the top 50 genes identified as being significantly up- or down-regulated by PcTx1 treatment for each spinal cord segment in animals with SIS scores of 2.5 (Table 3a) and 2.75 (Table 3b). Datasets for all genes with FC >2 or < -2 can be found in Tables S1 (see Supplementary file 1). As seen in Table 3a (SIS 2.5) the magnitude of highly up-regulated genes (FC>20) was highest in the rostral (10 genes) and injury segments (5 genes), whilst in the caudal segment no gene was up-regulated by more than FC 7.5, with most being less than FC 5. The largest FC in the down-regulated dataset, however, was identified in the caudal segment (FC -35.3). The three segments showed very little, if any, overlap in the top 50 up- or down-regulated genes (Tables 3a & 3b).

In contrast, a different pattern of expression was observed in animals with more severe injuries (SIS score of 2.75, Table 3b). In the rostral segment only one transcript was up-regulated by FC>20 and none were down-regulated by more than FC<-20. However, in both the injury and caudal segments there were several transcripts that were over 20 FC (both up- and down-regulated). The largest FC values were obtained for the caudal segment: two transcripts were up-regulated by FC>70 while three
Figure 7. Correlation between raw transcript numbers and initial injury severities (SIS scores) in the rostral segment of spinal cords from PcTx1-treated rats at 24 h post-injury (Illumina Platform). (a) shows the top 50 up-regulated genes, (b) the middle 50 unchanged genes and (c) the bottom 50 down-regulated genes (Table 3). Each line represents a single gene. Data shown are for the rostral segment, similar correlations were observed in the injury and caudal segments. Note, transcript numbers increased (a) or decreased (c) for each gene with increasing injury severity (SIS) score. This highlights the importance of using similar size initial injuries for comparative studies.
were down-regulated by FC<30 (Table 3b). Again, there was little, if any, overlap in the top 50 up- or down-regulated genes between the three segments.

The top 50 up-regulated and down-regulated genes for each segment were analysed by ‘String’ which orders them into functional protein association networks (Szklarczyk et al., 2015). These are illustrated in Supplementary file 2. A common feature of the protein association pathways was chemokine signalling (and immune response) related proteins. In both the SIS 2.5 and SIS 2.75 groups, PcTx1-treated rats showed up-regulation of chemokine-based signalling in the rostral segment and a down-regulation in the caudal segments. In the injury segment of the spinal cord initial injury severity appeared to be the key contributor to chemokine signalling – with a cluster of genes up-regulated in the SIS 2.5 group and a cluster down-regulated in the SIS 2.75 group. Along with chemokine-related proteins, smooth muscle associated proteins were up-regulated in the injury centre of the SIS 2.5 group. These results suggest PcTx1 may act through modifying the inflammatory response to SCI.

All of the gene transcripts with significant changes (i.e. FC>2 or FC<-2) for the two injury sizes (SIS 2.5 and 2.75) were separated into their biological categories (Figure 9) using the ‘Panther’ gene classification system (Mi et al., 2013). Genes classed as cellular (~21%) and metabolic (~18%) processes showed the most changes. Gene changes were also observed for apoptotic (~2%) and immune system (~5%) response – categories of potential importance to tissue preservation following SCI. However, when canonical genes known to be involved in the intrinsic and extrinsic apoptotic pathways (Elmore, 2007) were analysed individually, no differences between PcTx1-treated and saline-treated rats at any injury severity or in different regions of the cord were detected (Supplementary file 3). The change in caspase-3 levels barely reached significance (FC 2.2) in the rostral segment of SIS 2.5 PcTx1-treated compared to saline-treated animals. However, as a whole, these results suggest that PcTx1 treatment may not have a major influence on apoptotic pathways at the 24 h post-SCI time point.

Lists of markers for main cellular components of the central nervous tissue were obtained from (Anderson et al., 2016), see Supplementary file 4. Transcripts for neuronal markers were down-regulated for SIS 2.5 injuries in the rostral segment (rbFOX3 FC -2.8; SYT1 FC -2.3) and up-regulated in the caudal segment for SIS 2.75 injuries (rbFOX3 FC 6.6; SYT1 FC 4.5). A similar profile was observed for markers of astrocytes with down-regulation in the rostral segment of SIS 2.5 injured animals (Gfap FC -2.6; Aqp4 FC -3.1; Slc1a2 FC -4.2) and up-regulated in the injury segment of SIS 2.75 injured animals (Gfap FC 2.3; Aqp4 FC 2.5; Slc1a2 FC 3.3). No statistically significant differences were observed for oligodendrocyte markers (Olig1 and Olig2) or for myelin (MAG) at any injury size anywhere along the cord. Similarly, there were no significant differences in microglial markers anywhere along the cord (apart from Trem2 in the rostral segment of SIS 2.5 injured animals, FC 2.2). However, CD68 (a macrophage marker) was significantly up-regulated in rostral regions (FC 6.9 in SIS 2.5 and FC: 2.7 in SIS 2.75), but down-regulated for larger injury sizes in both the injury and caudal segments (SIS 2.75 FC -4.8 at injury centre and FC -2.2 in the caudal segment). CD14 and CCL2

![Figure 8. Comparison of the numbers of transcripts in the rostral, injury and caudal segments that changed (FC>2 or FC<-2) between PcTx1-treated and saline-treated animals. Datasets obtained from animals with 2.5 and 2.75 SIS scores. Negative values (red) indicate the number of down-regulation genes while positive values (blue) indicate the number of up-regulated genes.](image)
Table 3. Top 50 genes that at 24 h after SCI were either up-regulated or down-regulated in response to PcTx1 treatment. Data are shown for the injury centre segment and the immediately adjacent rostral and caudal segments for animals with SIS 2.5 injuries (a) or SIS 2.75 injuries (b). Fold changes (FC) were calculated from FPKM values (see Methods).

| Gene       | Up-regulated | Down-regulated | Up-regulated | Injury Centre | Down-regulated | Up-regulated | Caudal | Down-regulated |
|------------|--------------|----------------|--------------|----------------|----------------|--------------|---------|----------------|
| Cxcl2      | 20.2         | -18.5          | Slc17a7      | 41.1           | -29.8          | Scn10a       | 74      | -39.7          |
| Dnah8      | 18.4         | -12            | Kcnh7        | 27.7           | -29.3          | Ckm          | 73      | -32.2          |
| Rh60_X_0663.2 | 16.2       | -11.6          | Ksr2         | 26.8           | -27.1          | Mlyp1        | 42.3    | -32.2          |
| Gabrp      | 16.2         | -11.1          | Slc19a3      | -12            | -26            | Avil         | 28.6    | -21.8          |
| IL31ra     | 11.9         | -10.2          | Frmd3        | 25.8           | -21.7          | Car3         | 22.9    | -18.9          |
| LOC100361444 | 9.7         | -10.2          | Lbx1         | 22.1           | -19.5          | Tmnt1        | 16.9    | -18            |
| Sla2f3     | 8.6          | -10.2          | Opn4         | 17.5           | -18.4          | Scn11a       | 16.9    | -17.4          |
| I2ra       | 8.6          | -9.7           | Grin2a       | 16.8           | -16.3          | Myh1         | 16.1    | -16.1          |
| Cxcl3      | 8.3          | -9.3           | RGD1308544   | 16.6           | -16.3          | Actn3        | 13.7    | -15.1          |
| Il1r2      | 8.1          | -8.8           | Rasal1       | 14.8           | -16.3          | Gabrp        | 13.7    | -13.6          |
| Tfp2a      | 7.9          | -7.4           | Tbx15        | 14.8           | -16.3          | Kcnh8        | 12.7    | -13.4          |
| Twist2     | 7.9          | -7.4           | Lypd6b       | 14.1           | -16.3          | Sprn         | 10.6    | -13.2          |
| Art5c      | 7.6          | -7.4           | AABR07065531.5 | 13.8         | -15.6          | Acta1        | 10.2    | -12.8          |
| AABR07053509.2 | 7.6        | -7.1           | Slc26a8      | 13.8           | -14.6          | Typl         | 9.5     | -11.2          |
| Cica4l     | 7.5          | -7.1           | Nmu          | 13.8           | -14.1          | AABR07070246.1 | 9       | -11            |
| Fam111a    | 7.4          | -6.9           | Lgr5         | 13.8           | -13.5          | RGD1560672   | 9       | -10.4          |
| Cyp4f18     | 7.0          | -6.8           | Slc27a2      | 13.5           | -13.1          | Myl1         | 8.7     | -10.4          |
| Dusp5      | 7.0          | -6.6           | Hapln1       | 13.5           | -13            | Siglec8      | 8.6     | -10.4          |
| Lrc15      | 6.7          | -6.5           | RGD1560672   | 12.9           | -13            | Tusc5        | 8.3     | -9.5           |
| Nppb       | 6.5          | -6.5           | Crbp         | 12.9           | -12.6          | Is12         | 7.9     | -9.2           |
| Gdnf       | 6.5          | -5.7           | Shisa6       | 12.3           | -12            | Abca6        | 7.4     | -8.6           |
| Cyp27b1     | 6.5          | -5.6           | AABR07045621.1 | 12           | -11.9          | LOC100359656 | 6.9     | -8.5           |
| Oas3       | 6.5          | -5.6           | Mli2         | 12             | -11.6          | Zap70        | 6.7     | -8.5           |
| Ucn2       | 6.4          | -5.2           | AABR07070246.1 | 12           | -11.6          | Ill1         | 6.3     | -8.5           |
| AC091336.1 | 5.9          | -5.2           | Ckap126      | 12             | -10.8          | Slc26a3      | 6.3     | -7.9           |
| SIS 2.75 | Injury Centre | Up-regulated | Down-regulated | FC   | Gene   | FC   | Gene   | FC   | Gene   | FC   | Gene   | FC   |
|----------|---------------|--------------|----------------|------|--------|------|--------|------|--------|------|--------|------|
| Rostral  |               |              |                |      |         |      |         |      |         |      |         |      |
| Sna2     | -5.2          | Cnnp1        | 11.1           | 11.1 | Cnnp1  | 5.5  | Cnnp1  | 5.5  | Cnnp1  | 5.5  | Cnnp1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |

| Caudal   |               |              |                |      |         |      |         |      |         |      |         |      |
| Sna2     | -5.2          | Cnnp1        | 11.1           | 11.1 | Cnnp1  | 5.5  | Cnnp1  | 5.5  | Cnnp1  | 5.5  | Cnnp1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
| Snai2    | -5.2          | Prrn1        | 11.1           | 11.1 | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  | Prrn1  | 5.5  |
|                | Rostral | Injury | Caudal |
|----------------|---------|--------|--------|
| Response to Stimuli | -64  | 53    | 190   |
| Reproduction     | -13   | 2     | 46    |
| Multicellular organismal processes | -101 | 26    | 382   |
| Metabolic processes | -161 | 63    | -634  |
| Locomotion       | -2    | 3     | 7     |
| Localisation     | -118  | 33    | 367   |
| Immune system processes | -35  | 42    | 109   |
| Developmental processes | -104 | 35    | 335   |
| Cellular processes | -231 | 83    | 767   |
| Cellular component, organisation or biogenesis | -27  | 12    | 130   |
| Biological regulation | -119 | 43    | 392   |
| Biological adhesion | -21  | 14    | 89    |
| Apoptotic processes | -17  | 9     | 66    |

Figure 9. Biological characterization of the significantly (FC>2 or FC<-2) up-regulated (blue; positive) and down-regulated (red; negative) transcripts in response to PcTx1 treatment (‘Panther’ gene classification system, Mi et al., 2013). Separate datasets were obtained from animals with SIS scores of 2.5 (top, lighter bars) and 2.75 (lower, darker bars).
Figure 10. Temporal pattern of blood-spinal cord barrier disruption after SCI. (a) Extravasation of HRP (44 kDa) extending radially out from sites of injury at 2 h post-injury. (b) HRP is confined to the lumen of blood vessels at 24 h post-injury with no visible leakage around sites of injury. (c) Extensive leakage of the 10 kDa dextran rhodamine B is observed around sites of injury at 24 h post-injury. (d) at 5 days post-injury, 10 kDa dextran rhodamine B was always confined to the lumen of blood vessels. (e) diagrammatic summary of the period of blood-spinal cord barrier disruption after SCI vs the molecular size of the permeability tracers. The tracers: dextran fluorescein, 70 kDa DF; horseradish peroxidase, HRP 44 kDa, dextran rhodamine B (DRB 10 kDa), biotin-dextran-amine (BDA 3 kDa), biotin-ethylene-diamine (BED 0.3 kDa) were injected systemically 20 minutes prior to collection of tissue. A tick mark indicates the presence of visible tracer extravasation whereas a cross indicates that the tracers were confined to the lumen of blood vessels.
showed similar profiles to CD68. Thus, in contrast to apoptotic pathways, immune responses (either local or systemic) and astrocyte involvement appear to be affected by PcTx1 treatment at 24 h post-injury.

Temporal pattern of blood-SC barrier (BSCB) disruption

The different size permeability tracers exhibited different temporal patterns of BSCB dysfunction after SCI (Figure 10c). At 2 h and 12 h post-SCI, HRP (44 kDa) was observed diffusing radially out from regions of tissue damage into surrounding tissue (Figure 10a). At 24 h post-SCI, both HRP and the larger dextran fluorescein (70 kDa) were only visible within the lumen of intact blood vessels (see Figure 10b), indicating early restoration of BSCB function for large permeability tracers. All three of the smaller permeability tracers (up to 10 kDa in size) were observed outside blood vessels in and around the injury centre at 24 h, 2 days and 4 days post-SCI (Figure 10c). By 5 days post-SCI, BSCB function was restored for the smaller tracers with all confined to the lumen of blood vessels, and the lesion core, and no evidence of diffusion out into surrounding tissue (Figure 10d).

Discussion

In this study we investigated whether ASIC1a inhibition improves functional outcomes after traumatic SCI. We also determined the temporal pattern of blood-spinal cord barrier (BSCB) disruption after SCI to define the length of the “treatment window” when there is unrestricted access into the spinal cord. Transcriptomic analysis of spinal cord tissue at the injury centre and in adjacent rostral and caudal regions was performed to better understand the cellular pathways involved in PcTx1-mediated neuroprotection. Taken together, our data indicate that (1) the severity of the initial injuries directly influence long-term functional outcomes and (2) blockade of ASIC1a using a systemically administered peptide inhibitor significantly improves functional outcomes over a range of initial injury severities.

Blood-spinal cord barrier dysfunction

PcTx1-mediated inhibition of acid-sensing ion channels on spinal neurons and glial cells is crucially dependent on the peptide being able to access spinal cord tissue. Our data show there is a post-trauma “treatment window” for drug delivery that is inversely related to the size of the tracer. For compounds up to 10 kDa in size, the “treatment window” allows 4 days of unrestricted access to spinal cord tissue after SCI. Thus PcTx1 (4.6 kDa) would have been able to access spinal tissue for the entire 48 h treatment period investigated. In this study, dextran rhodamine B (10 kDa) was used as a surrogate tracer for the smaller PcTx1 because it can be directly visualized in fixed tissue sections and avoids the effects that labelling of PcTx1 would have on its physicochemical properties, pharmacological activity, solubility profile and biodistribution in vivo. In addition, our data show that BSCB disruption is highly localised to sites of injury, thus delivering PcTx1 directly to where it is needed (Figure 10).

Choice of injury model for assessing neuroprotection

In order to assess efficacy of treatments targeted at reducing the secondary expansion of tissue damage in the central nervous system, it is essential to use experimental models in which secondary tissue loss is a prominent feature. This requirement generally means using small to medium sized lesions as more severe primary lesions that occupy most or all of the cross sectional area of the cord leave little surrounding undamaged tissue into which secondary expansion can occur. For example, the absence of any significant neuroprotective effect in a large animal trial of MgPEG (Streijger et al., 2016), previously shown to be neuroprotective in rodents (Kwon et al., 2009), is probably due to the absence of any viable tissue to protect at the injury centre. In the present study, we used controlled impacts to the exposed thoracic spinal cord to produce moderate spinal cord lesions that are initially confined to the central grey matter. Thoracic level injuries enable hind limb function to be used as an assessment of preservation of white matter locomotor tracts. Lower level primary injuries involving lumbar grey matter will cause the loss of lower motorneurons that connect between the spinal cord and individual hind limb muscles. Without lower motorneuron connections, preservation of upper motorneurons in white matter tracts will not be functionally detectable.

Initial injury severity scoring

To reliably assess the therapeutic effectiveness of treatments to limit secondary tissue loss after SCI, it is essential that comparisons are made between animals that started with similar sized initial injuries, otherwise it cannot be determined if smaller lesions in treated animals at later time points are due to the treatment effect or smaller initial injuries in those animals. Most experimental impactor devices give control over one or more aspects of the impact (force, velocity, depth of tissue penetration and length of compression). It is generally assumed that uniform impacts will produce uniform initial injuries, however this has not been well investigated. The results obtained in this study using highly reproducible contusion impacts to the spinal cord (0.30 m/s ± 0.04 S.D. velocity, 1.44 mm ± 0.01 S.D. penetration, 0.997s ± 0.004 S.D. compression time) showed marked differences in the severity of initial functional deficits between animals (SIS range 1.9–2.75, Figure 2a), scores that reflect marked differences in animals’ abilities to flex hind limb joints (Table 2). The reason for this variance is likely to be due to inter-animal differences in the number and location of blood vessels that are damaged by the impact, the extent of haemorrhage that occurs and the size of the ensuing region of downstream hypoperfusion. Thus caution needs to be exercised when using aggregate analysis to compare group means between treated and untreated SCI animals. Assessing the severity of functional deficits (or MRI assessments of the extent of tissue damage) soon after injuries are made enables treatment effects to be followed over time within individual animals. The SIS grading scale developed in this study used a small number of simple yes/no objective criteria (does the animal show hind limb weight support, how many hind limb joints can it extend and flex, Table 2), yet yielded very accurate results. Larger initial SIS scores were predictive of greater total amounts of tissue loss (Figure 5) and poorer residual functional (Figure 2a) by 6 weeks post-injury. Early assessment of hind limb function has only been employed in a small number of previous SCI studies (Anderson et al., 2016; Herrmann et al., 2008), but given the variability of lesion sizes observed using highly standardised impacts, we would encourage routine inclusion of initial injury severity measurements in future SCI studies.
Hind limb functional assessments

Hind limb function is not exclusively driven and modulated by inputs from the brain. Proprioceptive and cutaneous sensory inputs have been shown to be able to drive local motor pattern generators in the spinal cord and generate hind limb stepping locomotion in the absence of any spinal cord connections to or from the brain (Grillner & Wallen, 1985; Rossignol, 1996). However, these local inputs are greatly reduced, if not absent, when swimming and this provides a useful objective test for the presence of descending supraspinal drive of hind limb locomotor function (Saunders et al., 1998; Wheaton et al., 2011). All of the SCI animals (PcTx1-treated and saline-treated) were able to swim using alternating kicks of their hind limbs when placed in a tank of water indicating preservation of some supraspinal drive to the lumbar motor centres of the hind limbs. If no functional connections between the brain and lumbar motor centres are present, then differences in hind limb function would not be reflective of preservation of descending white matter tracts.

Most of the locomotor function tests used in this study indicated greater preservation of function at 6 weeks post-injury in the PcTx1-treated animals. The BBB locomotor analysis showed a highly significant improvement in hind limb function of approximately 2 points on the BBB scale in the PcTx1 treated animals (Figure 2a) that was apparent across the entire range of injury severities investigated. Although that is a modest increase numerically, the effect on locomotor function can be disproportionately large. An increase from 11 to 12 on the BBB scale, for example, corresponds to the difference between the presence and absence of fore limb–hind limb coordination. The PcTx1-treated animals also exhibited fewer foot faults in the horizontal ladder test compared to saline-treated equivalents indicating improved ability to perform coordinated motor tasks following SCI. Two animals with very high SIS scores (one PcTx1-treated and one saline-treated) had many more foot faults than the other rats (Figure 2b). As an SIS score of 3 indicates complete paralysis (and therefore more extensive initial trauma), it is not surprising that animals with scores close to this would perform poorly on the ladder test.

In contrast to results from the BBB and ladder tests, PcTx1 treatment did not improve motor function on the tapered beam test. A range of factors may have contributed to this. The animals making the most foot faults had a wide range of SIS scores suggesting that walking with legs pressed close together under the body when on the thinnest part of the beam might be difficult for rats of any injury severity. It was also apparent that, after a few trials, many rats learnt that they could walk along the beam using the lower counting ledge without falling and did not even attempt to stay on the narrow beam in subsequent trials. This made it difficult to distinguish between voluntary and involuntary use of the error-counting ledge.

Tissue preservation

A striking feature of the present study was the complete absence of the central grey matter and large amounts of surrounding white matter at the injury centre (Figure 4). Immunohistological analysis of serial sections spanning the length of the injured cord segment revealed no significant differences in the number of FOX3 positive neurons between the PcTx1-treated and saline-treated animals at either 24 h or 6 weeks post-injury. In addition, there was no significant change in the number of FOX3 positive neurons between 24 h and 6 weeks which is consistent with our earlier study showing that trauma-induced secondary loss of neurons in the central grey matter is largely complete by 24 h post-injury (Ek et al., 2010; Ek et al., 2012).

CNPase staining of white matter also showed no significant differences in total white matter area between the PcTx1-treated and saline-treated animals at 6 weeks post-injury despite the significant improvements in locomotor function that were observed in these animals. We investigated further whether the improvements in hind limb function might be due to greater preservation of individual descending white matter tracts that are known to be involved in motor function. A study using injections of biotinylated dextran amine into the motor cortex of mice (Steward et al., 2004) highlighted three main regions of descending corticospinal motor tracts; at the base of the dorsal column (dcCST), in the dorsolateral white matter on the ventral side of the dorsal horns (dlWM) and in the ventromedial white matter (vmWM) either side of the sulcal fissure. In the present study, the dcCST which normally carries the majority of the descending motor fibres (Kathe et al., 2014; Steward et al., 2004) was completely absent at 6 weeks post-injury (Figure 1 & Figure 4) in all of the PcTx1-treated and saline-treated animals. Since all of these animals were able to swim using their hind limbs and recorded high BBB scores this suggests that the dcCST is not essential for driving coordinated hind limb motor function. Detailed analysis of the dlWM region using three separate histological stains (LFB, CNPase and H&E) on adjacent slides from the injury centre showed a greater preservation of white matter in the PcTx1-treated animals compared to saline-treated controls at 6 weeks post-injury (Figure 5). The total area of preserved dlWM showed an inverse correlation with initial injury severity scores (Figure 5) and a positive correlation with BBB functional scores (Figure 6a).

Preservation of tissue in the vmWM region that normally contains reticulospinal tracts was highly variable and there were no apparent correlations between white matter area in this region and any of the behavioural tests or with the severity of the initial injuries as measured by SIS score.

There was however a noticeable difference in the appearance of the myelin within this region between the treatment groups (Figure 4). In PcTx1-treated animals, there was an improvement in the quality of the myelin and a decrease in the amount of axotomised axons (Figure 4). Taken together, these results suggest that it is preservation of axons in the dlWM that is mainly responsible for the improvements in hind limb function in the PcTx1-treated animals.

Mechanism of neuroprotection

RNaseq differential expression analysis revealed a number of genes whose transcript levels were significantly altered in the
PcTx1-treated SCI animals compared to saline-treated SCI animals. Subsequent analysis of transcript variance of the up- and downregulated genes also revealed marked differences in transcript numbers between animals with different injury severities (Figure 7). Animals with less severe injury severities (e.g. SIS 1.9) exhibited much lower gene transcript numbers for the up-regulated genes and much higher transcript numbers for the down-regulated genes when compared to animals with more severe injuries (e.g. SIS 2.5). This may be due to different magnitudes of the biological responses to injury sizes (such as inflammation levels) that are sensitive to PcTx1. It might also be due to greater vascular disruption in the larger injuries allowing greater extravasation of PcTx1 into the injury site. These pronounced effects of injury severity on gene expression and hind limb functional performance highlight the need to conduct early post-surgery analysis of injury severity in order to compare animals with very similar initial injuries. Aggregating SCI data to conduct parametric statistical analysis using group means is likely to increase the incidence of type 2 statistical errors.

Unique profiles were also observed between the different cord regions (rostral, injury centre and caudal) in terms of the number and complement of genes that changed their expression levels (Figure 8). This may partly reflect different pathological processes in the different regions, ‘primary’ necrotic damage localized to the injury centre (Ek et al., 2012) and secondary ischaemic damage away from the injury centre. Another contributing factor could be the predominantly rostral to caudal direction of arterial blood flow at the T10 level of the spinal cord and the rostral to caudal angular orientation of sulcal arteries supplying the central grey matter (Figure 11b). Thus disruption of grey matter vessels at the injury site might result in less perfusion (and consequent greater hypoxia ischaemia) below the injury site compared to higher rostral segments (Ek et al., 2010). These results highlight that the pathophysiology of SCI is not homogeneous along the injured cord segment and that neuroprotective treatments may exhibit different efficacies in different areas of the spinal cord and for different injury severities.

PcTx1 treatment did not significantly alter the expression of genes for myelin or oligodendrocytes, which is in contrast to the histological results showing greater preservation of myelin. Similarly, down-regulation of neuronal markers in PcTx1-treated SIS 2.5 animals in the rostral segment and up-regulation in the injury segment in PcTx1-treated SIS 2.75 animals was also at odds with the histological results. The discrepancy between
these results may highlight that the main transcriptomic changes occurred at different time-points to the protein changes. It could also mean that individual animals respond to treatment and injury at varying speeds within the first few days.

An interesting observation was an inverse relationship between expression of neuronal and inflammatory markers. In the rostral region of PcTx1-treated SIS 2.5 animals, transcript numbers for neuronal and astrocyte markers were significantly decreased, whilst transcript numbers for the inflammatory markers CD68, CCL2 and CD14 were significantly increased. Conversely, transcript numbers for neuronal and astrocyte markers were significantly increased at the injury centre in PcTx1-treated SIS 2.75 animals, whilst transcript numbers for the three inflammatory markers were significantly decreased. Attenuation of the enriched immune system related pathways (such as CCL2 and CD14) has been proposed as a potential treatment for SCI (Wen et al., 2016). Our results suggest that PcTx1-mediated effects on the immune response may be an integral component for functional recovery following SCI.

PcTx1 also affected expression of genes encoding for smooth muscle related proteins. This was particularly apparent at injury centre in animals with SIS 2.5 injuries (Supplementary file 2). Due to the prominent role vascular disruption plays in spinal injury severity, alterations in blood flow might contribute to the effects observed from PcTx1. Future investigation into this topic would be beneficial to the field.

It has been proposed that the neuroprotective effects of ASIC1a inhibitors may be due to prevention of activation of the intrinsic apoptotic pathway (Friese et al., 2007; Gao et al., 2005; Xiong et al., 2004; Yermolaieva et al., 2004). It has been postulated that acidosis in areas of acute tissue ischaemia opens ASIC1a channels allowing the influx of Na+ ad Ca2+ into neurons and glia. This is thought to cause mitochondrial membrane depolarisation, release of cytochrome c and subsequent activation of intrinsic apoptotic cell death pathways (Friese et al., 2007; Sherwood et al., 2011; Smaïl et al., 2003). A review by Elmore (2007) describes the key proteins involved in the intrinsic, extrinsic and final execution apoptotic pathways. We did not observe down-regulation of any of the key genes in these apoptotic pathways in the PcTx1-treated animals at 24 h post-SCI (Dataset 1, Table S3). Thus the neuroprotective effects of PcTx1 may not be mediated by a modulation of apoptotic cell death. There remains, however, the possibility that PcTx1 could inhibit apoptotic pathway activation at earlier stages of tissue damage prior to 24 h post-SCI. Previous research in rats has shown increased expression of many inflammatory genes (e.g. IL1β, IL6, MIP2 and MIP1α) in the initial 6–12 h post-SCI before declining to values approaching control levels between 24 h and 48 h (Carmel et al., 2001). As the transcriptomic analysis in this study was only conducted at a single time point (24 h), there remains the possibility that PcTx1 has even greater effects on earlier phases of the inflammatory response to SCI.

Concluding remarks

In the spinal cord, “tissue is function” and it is widely accepted that the extent of functional losses after SCI reflects the extent of tissue loss (injury size). It remains to be determined why PcTx1 appeared to primarily preserve white matter (or myelin levels) in the dlWM regions and not in other myelinated tracts within the cord. One possibility is that the model of injury used in this study (central dorsal contusion) disproportionately affects some regions of the cord compared to others. The central grey matter and vmWM regions, for example, lie immediately under the impact site whilst the dlWM is to the side and less directly impacted. Another possibility is that there could be important structural differences between the different areas of the cord. The dlWM may contain a greater proportion of blood vessels originating from the outer pial surface, which would retain greater perfusion, compared to areas with blood vessels originating from the central sulcal (grey matter) supply (Figure 11a). In order to reveal whether there is evidence of preservation in other areas not visible at the light microscope level, higher resolution analysis of white matter structure at the EM level would be required. For example, greater numbers of myelin sheath wrappings around axons could explain some of the difference in myelin integrity observed between PcTx1-treated and saline-treated animals seen in the vmWM (Figure 4).

Transcriptomic analysis highlighted several possible mechanisms for the neuroprotective effects of PcTx1 after trauma. Whilst PcTx1 did not appear to affect apoptotic cell death pathways at 24 h post injury, it did alter expression levels of genes involved in inflammatory and immune responses. Further transcriptomic analysis at earlier time points may lead to a better understanding of the mechanisms involved and their timing. In conclusion, this study shows that PcTx1 is effective at preserving white matter tracts involved in hind limb function and thereby improving behavioural outcomes following SCI in the rat.

Dataset 1. Raw transcript data for PcTx1- and saline-treated adult rats 24 h after spinal cord injury

http://dx.doi.org/10.5256/f1000research.9094.d128164

Raw gene transcript data (Illumina Platform) for PcTx1-treated (n=3) and saline-treated (n=3) adult rats 24 h after mid-thoracic spinal cord injury. The top row shows the injury severity (SIS) score for each animal during the first 24 h post-injury. The second row shows the animal IDs, treatment groups and spinal cord regions. Column a = geneid. Columns b, c, d = rostral segments from saline-treated animals 1, 2, 3. Columns e, f, g = rostral segments from PcTx1-treated animals 4, 5, 6. Columns h, i, j = injury centre segments from saline-treated animals 1, 2, 3. Columns k, l, m = injury centre segments from PcTx1-treated animals 4, 5, 6. Columns n, o, p = caudal segments from saline-treated animals 1, 2, 3. Columns q, r, s = caudal centre segments from PcTx1-treated animals 4, 5, 6.

Data availability

F1000Research: Dataset 1. Raw transcript data for PcTx1- and saline-treated adult rats 24 h after spinal cord injury, 10.5256/f1000research.9094.d128164 (Koehn et al., 2016).

Author contributions

MDH, KMD, NRS, LDR and GFK conceived and planned the study. LMK, NMN and QD performed most of the analytical work, MDH was responsible for all animal surgeries, KMD supervised
Supplementary material

Supplementary file S1. PcTx1-induced fold changes (FC) in gene expression after SCI.
Lists of genes with FC >2 or FC <-2 changes in transcript counts at 24 h post-SCI in response to PcTx1 treatment in the rostral (Table S1a), injury centre (Table S1b) and caudal spinal cord segments (Table S1c).
Click here to access the data.

Supplementary file S2. Functional protein association networks for gene changes in PcTx1-treated animals after SCI.
Functional protein association networks of transcripts that were up-regulated or down-regulated in the injury segment of PcTx1-treated animals compared to saline-treated animals. (a) SIS 2.5 and (b) SIS 2.75 animals. Connecting lines indicate associations between the protein products as determined by the ‘String’ network system (Szklarczyk et al., 2015). Transcripts were obtained from RNAseq (Illumina).
Click here to access the data.

Supplementary file S3. Effects of PcTx1 on apoptotic pathway expression after SCI.
Fold changes (FC) of transcript counts for canonical genes in the intrinsic, extrinsic and converging execution apoptotic pathways at 24 h after SCI. Positive values indicate that transcript counts were up-regulated in PcTx1-treated animals compared to saline-treated animals and negative values indicate lower transcript counts for the PcTx1-treated animals. Lists of genes were obtained from Elmore (2007). Transcript counts were obtained from RNAseq (Illumina).
Click here to access the data.

Supplementary file S4. Effects of PcTx1 on expression of cell specific markers after SCI.
Fold change (FC) of transcript counts of genes for cellular markers for astrocytes, neurons, oligodendroglia, microglia and endothelial cells at 24 h after SCI. Positive values indicate that transcript counts were up-regulated in PcTx1-treated animals compared to saline-treated animals and negative values indicate lower transcript counts for the PcTx1-treated animals. Lists of genes were obtained from Anderson et al. (2016). Transcript counts were obtained from RNAseq (Illumina).
Click here to access the data.

References

Abramoff MD, Magalhães PJ, Ram SJ: Image processing with ImageJ.
Biophotonics Intern. 2004; 11: 36–42.
Reference Source
Amar AP, Levy ML: Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery. 1999; 44(5): 1027–1039; discussion 1039–40.
PubMed Abstract | Publisher Full Text
Anderson MA, Burda JE, Ren Y, et al.: Astrocyte scar formation aids central nervous system axon regeneration. Nature. 2016; 532(7588): 195–200.
PubMed Abstract | Publisher Full Text
Baron A, Voilley N, Lazzunski M, et al.: Acid sensing ion channels in dorsal spinal cord neurons. J Neurosci. 2008; 28(6): 1468–1508.
PubMed Abstract | Publisher Full Text
Basso DM, Beattie MS, Bresnahan JC: A sensitive and reliable locomotor rating.
Smith RR, Burke DA, Baldini AD, et al. Mitochondria, calcium and pro-apoptotic proteins as mediators in cell death signaling. Braz J Med Biol Res. 2003; 36(2): 183–190.

PubMed Abstract | Publisher Full Text | Free Full Text

Small SS, Hu Y, Carvalho AC, et al. Extracellular acidosis increases neuronal calcium-permeable acid-sensing ion channels and improves behavioral recovery after spinal cord injury. J Neurosci. 2011; 31(26): 9723.

PubMed Abstract | Publisher Full Text | Free Full Text

Yin T, Lindey TE, Albert GW, et al. Pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol. 2008; 8(1): 25–32.

PubMed Abstract | Publisher Full Text | Free Full Text

Xiong ZG, Pignataro G, Li, et al. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol. 2008; 8(1): 25–32.

PubMed Abstract | Publisher Full Text | Free Full Text

Wolman L. The disturbance of circulation in traumatic paraplegia in acute and late stages: a pathological study. Paraplegia. 1965; 2: 213–226.

PubMed Abstract | Publisher Full Text

World Health Organization: Fact sheet 384 – spinal cord injury. 2013; [Accessed: 30th May 2016]

Reference Source

Wu LJ, Duan B, Mei YD, et al. Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord. J Biol Chem. 2004; 279(42): 43716–43724.

PubMed Abstract | Publisher Full Text

Wu WN, Wu PF, Chen XL, et al. Sinomenine protects against ischaemic brain injury: involvement of co-inhibition of acid-sensing ion channel 1a and L-type calcium channels. Br J Pharmacol. 2011; 164(5): 1445–1459.

PubMed Abstract | Publisher Full Text | Free Full Text

Xiong ZG, Chu XP, Simon RP. Ca²⁺-permeable acid-sensing ion channels and ischemic brain injury. J Membr Biol. 2006; 209(1): 59–68.

PubMed Abstract | Publisher Full Text

Xiong ZG, Pignataro G, Li, et al. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol. 2008; 8(1): 25–32.

PubMed Abstract | Publisher Full Text | Free Full Text

Xiong ZG, Zhu XM, Chu XP, et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell. 2004; 118(6): 678–688.

PubMed Abstract | Publisher Full Text

Yermolaieva O, Leonard AS, Schnizler MK, et al. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proc Natl Acad Sci U S A. 2004; 101(17): 6752–6757.

PubMed Abstract | Publisher Full Text | Free Full Text

Yin T, Lindey TE, Albert GW, et al. Loss of Acid sensing ion channel-1a and bicarbonate administration attenuate the severity of traumatic brain injury. PLoS One. 2013; 8(8): e72379.

PubMed Abstract | Publisher Full Text | Free Full Text

Zhang N, Yin Y, Xu SJ, et al. Inflammation & apoptosis in spinal cord injury. Indian J Med Res. 2012; 135: 287–296.

PubMed Abstract | Free Full Text

Zheng Z, Schwab S, Grau A, et al. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. Brain Res. 2007; 1186: 275–280.

PubMed Abstract | Publisher Full Text

Zhou X, Lindsay H, Robinson MD. Robustly detecting differential expression in RNA sequencing data using observation weights. Nucleic Acids Res. 2014; 42(11): e91.

PubMed Abstract | Publisher Full Text | Free Full Text

Wolman L. The disturbance of circulation in traumatic paraplegia in acute and late stages: a pathological study. Paraplegia. 1965; 2: 213–226.

PubMed Abstract | Publisher Full Text

World Health Organization: Fact sheet 384 – spinal cord injury. 2013; [Accessed: 30th May 2016]

Reference Source

Wu LJ, Duan B, Mei YD, et al. Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord. J Biol Chem. 2004; 279(42): 43716–43724.

PubMed Abstract | Publisher Full Text

World Health Organization: Fact sheet 384 – spinal cord injury. 2013; [Accessed: 30th May 2016]

Reference Source

Wu WN, Wu PF, Chen XL, et al. Sinomenine protects against ischaemic brain injury: involvement of co-inhibition of acid-sensing ion channel 1a and L-type calcium channels. Br J Pharmacol. 2011; 164(5): 1445–1459.

PubMed Abstract | Publisher Full Text | Free Full Text

Xiong ZG, Chu XP, Simon RP. Ca²⁺-permeable acid-sensing ion channels and ischemic brain injury. J Membr Biol. 2006; 209(1): 59–68.

PubMed Abstract | Publisher Full Text

Xiong ZG, Pignataro G, Li, et al. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol. 2008; 8(1): 25–32.

PubMed Abstract | Publisher Full Text | Free Full Text

Xiong ZG, Zhu XM, Chu XP, et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell. 2004; 118(6): 678–688.

PubMed Abstract | Publisher Full Text

Yermolaieva O, Leonard AS, Schnizler MK, et al. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proc Natl Acad Sci U S A. 2004; 101(17): 6752–6757.

PubMed Abstract | Publisher Full Text | Free Full Text

Yin T, Lindey TE, Albert GW, et al. Loss of Acid sensing ion channel-1a and bicarbonate administration attenuate the severity of traumatic brain injury. PLoS One. 2013; 8(8): e72379.

PubMed Abstract | Publisher Full Text | Free Full Text

Zhang N, Yin Y, Xu SJ, et al. Inflammation & apoptosis in spinal cord injury. Indian J Med Res. 2012; 135: 287–296.

PubMed Abstract | Free Full Text

Zheng Z, Schwab S, Grau A, et al. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. Brain Res. 2007; 1186: 275–280.

PubMed Abstract | Publisher Full Text

Zhou X, Lindsay H, Robinson MD. Robustly detecting differential expression in RNA sequencing data using observation weights. Nucleic Acids Res. 2014; 42(11): e91.

PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Referee Status: ✔️ ✔️

Version 2

Referee Report 19 December 2016

doi:10.5256/f1000research.11107.r18324

David Magnuson, Darlene Burke
Kentucky Spinal Cord Injury Research Center, University of Louisville, Louisville, KY, USA

The authors were responsive to our concerns and either made appropriate changes or provided well reasoned explanations for why they chose not to. The paper is improved and in particular the description of the statistical analysis and use of the F statistics are now much easier to follow.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Version 1

Referee Report 30 September 2016

doi:10.5256/f1000research.9788.r15249

Helen Marie Bramlett
Department of Neurological Surgery, University of Miami, Miami, FL, USA

This manuscript reports on the use of a novel injury severity score for spinal cord injury to determine treatment efficacy on histological, functional and transcriptomic outcome measures. The treatment chosen was a selective inhibitor of ASIC1a, PcTx-1. The authors compared extensively through correlation how PcTx-1 improves function as well as white matter preservation based on the individual animal’s severity score. Overall, this treatment appears to improve several outcome measures but did not significantly impact the transcriptome analysis targeting the apoptosis pathway. However, the use of the injury severity score has merit when determining drug efficacy because individual animals are analyzed based on this score. When using this type of analysis, the heterogeneity of SCI can be taken into consideration.

Specific Comments:
1. Overall, this is a well-written manuscript. However, several minor points are at issue.
2. The authors state that the use of the osmotic pump for PcTx1 release resulted in stable plasma concentrations of the drug over a 48 hr period, how was this determined? Were levels taken or was this an assumption?

3. In using the beam test, animals are usually pretrained on this task but there is no mention of this in the methods section.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

---

**Author Response 22 Nov 2016**

Mark Habgood, University of Melbourne, Australia

*"The authors state that the use of the osmotic pump for PcTx1 release resulted in stable plasma concentrations of the drug over a 48 hr period, how was this determined? Were levels taken or was this an assumption?"*

Yes this was an assumption.

The role of the pump was to slowly and steadily release PcTx1 (1.08 μg/h) subcutaneously to compensate for estimated renal and tissue losses over a 48 h period.

PcTx1 is a cysteine knot peptide which makes it very stable and resistant to plasma peptidases with a half-life >12 hours (unpublished). Thus, *in vivo*, the main plasma losses are due to renal excretion

*"Pre-training"*

The animals were pre-trained on the beam apparatus prior to commencement of the surgical and treatment protocols. On the day of functional testing, the animals were allowed 3 practice runs prior to recording. This information has been added to the Methods.

**Competing Interests:** No competing interests were disclosed.
The investigators chose to use a novel SIS (simplified injury severity) score at the time of injury and again at 24 hours post-injury. The SIS is based on a rather coarse and certainly non-linear 6-point scale (0-3 in 0.5 unit increments). Nonetheless, the 24h SIS score plays a very important role in the paper. Functional assays at 24h, whether they be visual scales like the BBB or video based kinematics, are poor predictors of terminal hindlimb function when moderate to severe injuries are used because most of the animals will exhibit flaccid paralysis at that early time point. In this paper they show that the SIS at 24 hours is predictive of terminal hindlimb function (BBB scores) following the mild injuries employed, even when only part of the scales range is used (1.5 – 2.75).

The other functional assessments included the BBB Open Field Locomotor Score (without subscore), horizontal ladder and tapered beam tasks and swimming, the last three utilizing video to assist with counting footfalls/slips and to assess hindlimb alternation. Interestingly, the investigators found significant functional differences only using ANCOVA analysis of BBB scores at 6 weeks vs initial injury severity score (SIS). No differences were seen in ladder, tapered beam or swimming, although the pattern of data points is somewhat suggestive that PcTx1 treatment reduced errors on the horizontal ladder.

This paper also presents a substantial amount of data on gene expression at 24h post-injury using the Illumina platform and marker extravasation at various time points. These data provide a lot of food for thought but unfortunately do not really allow any strong conclusions to be drawn except that the blood spinal cord barrier remains leaky to small markers for up to 4 days after a mild contusive spinal cord injury thus providing a window of pharmacological opportunity wherein small molecules, like PcTx1, may enter the spinal cord from the bloodstream to confer protection.

Major Concerns:

1. The primary finding of the paper, that PcTx1 improves locomotor function of adult SD rats after thoracic SCI is only partly supported by the data. Traditionally, the BBB and other functional (and hopefully objective) assessments would be done weekly and changes over time would be observed. Group differences in BBB or BBB subscore along with objective kinematic or gait analysis would be used to conclude that a tissue-sparing strategy resulted in functional improvements or it did not. In this case the authors chose to assess the locomotor function at 6 weeks only and to reduce the effect of inter-animal variability using the 24h SIS scores and ANCOVA analysis.

2. Using ANCOVA is unusual in this kind of experiment, but can be done only if the correlation coefficients of the two groups are equal, and this information has not been provided. For each of the regression lines a 95% confidence interval should be shown. For the BBB vs SIS data, it should also be explained what test was done to determine that the PcTx1-treated group had a “significantly higher elevation compared to the saline-treated group”. It is assumed that this is part of the ANCOVA analysis, but more details should be given. Similarly, for the dlWB vs SIS data, it should be explained what test was done to determine significance and 95% confidence intervals should be shown. The outcomes of these tests should also be provided for the other data sets shown in Figures 2 and 6, even if there are no significant differences.

Minor Concerns:

1. In the subsection “Functional Testing” the authors suggest that hindlimb alternation during swimming is indicative of supra-spinal connections without giving a reference. Subsequently, in the results section they indicate that there were no differences in swimming between the groups. This is meaningful only if the analysis was extended beyond the presence or absence of alternation and
I believe more information is necessary or perhaps the reference to swimming should be removed as it adds nothing to the paper. We have used swimming extensively in my laboratory and have seen animals with a wide range of spared white matter accomplish hindlimb alternation.

2. If notes were taken during the BBB scoring it should be possible to determine the BBB subscores that have proven to be very helpful in other studies using mild thoracic injuries.

3. In the section “Blood-spinal cord barrier integrity” the authors reference using an overdose of inhaled anesthetic. It is recommended in the AVMA Guidelines on Euthanasia that a secondary method of ensuring death is employed and this should be described here.

4. In this same section it is obvious that an additional cohort (or cohorts) of animals were employed to develop the time course/size of tracer relationship and these animals should be included at the beginning of the methods section to indicate the real total of animals used in the studies.

5. For histological analysis the investigators chose to assess dorsolateral funiculus, ventral white matter and corticospinal tracts using a myelin stain. While this is acceptable, the rationale for these choices includes “white matter tracts involved in hind limb motor function”. While this statement is true, it is not complete. There are many examples in the literature demonstrating that the ventrolateral and lateral white matter are at the top of the hierarchy for hindlimb function. Thus, including the lateral and ventrolateral white matter in the analysis would be ideal, but at the very least the statement should be amended to indicate that the areas chosen are among those involved in hindlimb function after SCI. With this caveat, the investigators have done an excellent job of analyzing spared white matter and pointing out the poor appearance of ventral tracts.

6. Comments in the discussion point to the non-linearity of the BBB scale and suggest that a mean difference of 1 or 2 points may be small (on the scale) but functionally significant. This may be true for certain ranges of the BBB (8-10 or 11-13), but is arguable not true for the range used here (16-18). A more sensitive gait assessment where order and timing of paw placement would have been helpful in this situation.

Figures:

1. The images in Figure 1 have quite different backgrounds which may add unwarranted contrast to the injured image (right). This should be corrected.

2. The indicator of significant differences in Figures 2 and 5 should be made more obvious. Increasing the size and blackness of the font and line/arrows should suffice.

3. The size of the font used in the legends is inconsistent and in some cases is too small (Figure 6).

4. The image in Figure 11b is too small and the text is way too small.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Competing Interests: No competing interests were disclosed.
Mark Habgood, University of Melbourne, Australia

The investigators chose to use a novel SIS (simplified injury severity) score:

The injury severity scale was used primarily to provide an index of the degree of initial dysfunction resulting from the contusion injury. In many experimental studies it is generally assumed that uniform mechanical impacts applied to the same spinal cord locations will produce very similar injuries with similar degrees of dysfunction. However, we have found that this is not the case and that the degree of initial dysfunction is much more variable and appears to depend on the extent and location of the initial damage and vascular disruption/haemorrhage.

The scale was intentionally developed to use hind limb motion features that are readily apparent to an observer and do not require more subjective interpretation (e.g. can the animal weight support it’s hindquarters or not). The scale is undoubtedly non-linear, a feature in common with most locomotor functional scales used in the field (e.g. BBB scale), but it is proportional. Less severe injuries give lower values than more severe injuries.

The scale does play an important role in the paper and this is a major point that we are trying to emphasise. The inherent variability of the initial injuries needs to be taken into account individually when assessing improvements in functional performance.

“Functional assays at 24h, whether they be visual scales like the BBB or video based kinematics, are poor predictors of terminal hindlimb function when moderate to severe injuries are used because most of the animals will exhibit flaccid paralysis at that early time point.”

Temporary flaccid paralysis is much less common after light to moderate injuries where less tissue damage is involved. In our study, none of the animals exhibited flaccid paralysis, all had some residual ability to move some or all of their joints. The scores assessed during the first 24 hours post-injury were found to correlate with long term functional outcomes.

Less severe injuries were intentionally used in this study because the focus was treatment-induced reductions of secondary tissue damage expansion using hind limb function as one assay of effectiveness. With thoracic spinal cord injuries, it is the white matter tracts that are primarily involved in supraspinal control of hind limb function. With more severe injuries, the primary damage zone often includes large areas of the white matter tracts which leaves little room for radial secondary expansion. In this study, the initial injuries (confirmed by histology at 15 minutes post-SCI) were confined to the central grey matter with little involvement of surrounding white matter tracts (Ek et al., 2010).

Major Concerns:

1. It is well known in the field that recovery of function after spinal contusion injury gradually improves over the course of several weeks until it reaches a plateau. We chose 6 weeks post-injury as being a time point well after the plateau in functional recovery. Our objective was to determine what was the ultimate level of functional recovery that could be achieved following 48 hours treatment commencing immediately after injury (i.e. were their long term functional improvements). The rate of functional recovery was not an objective of the study.

We agree that kinematic analysis could provide valuable detailed analysis, however this is often
not available in many parts of the world. Therefore we wanted to demonstrate that even using simple and easily available techniques that targeting ASIC1a demonstrate significant differences providing the experimental design takes into account the variance of initial injuries.

Use of first 24 hours SIS scores.
In this study we have shown that almost identical mechanical contusion impacts (see Results for impact velocity, tissue penetration and compression time) result in a variable range of initial dysfunction and thus the assumption that all animals are starting from the same functional level is not correct. Furthermore, we have also shown that the long-term functional outcome of individual animals correlates linearly with the degree of initial dysfunction (i.e. within each group, the differences in initial injuries are contributing to the observed differences in ultimate functional outcomes).

Our opinion is that ignoring the presence of a known source of variance in order to use parametric testing will increase the likelihood of making a Type 2 statistical error (i.e. by assuming that the covariate has no influence on the measurements being made).

2.
Tests for equal slope (correlation coefficients) are part of the ANCOVA.
The ANCOVA software (PRISM 6.0, Graphpad) uses the general linear model approach which fits linear regression lines to the datasets and then tests whether the slopes (correlation coefficients) are similar. If the slopes are confirmed to be the same, differences in the intercepts (elevations) can then be tested. If the slopes are not the same, differences in the intercepts cannot be calculated.

As part of the statistical analysis, the two data groups being compared (i.e. control and PcTx1-treated) were analysed to determine if they were best described by (a) a single data group (i.e. there were no differences in slopes or intercepts), (b) two separate groups with different slopes or (c) two separate groups with the same slope, but different intercepts. In the text we have used the phrase “the data were best described by two separate lines with the same slope” to indicate that the slopes (correlation coefficients) were found to be the same. We have also added additional statistical information to the figure legends where appropriate (F statistic with degrees of freedom).

The suggestion of adding 95% confidence intervals is excellent and these have been added to figures where appropriate.

“It is assumed the test to determine significantly higher elevations is part of the ANCOVA.”
Yes, this is a fundamental part of the ANCOVA. The slopes (correlations) are tested first and if confirmed to be the same, differences in the intercepts (elevations) are then tested. The mathematics involved in the software is an F test. We have revised the figure legends to include the pooled slopes where significant differences are shown, and the F statistics for the comparisons. We have also added the name of the software package used for the ANCOVA (PRISM 6, Graphpad) and further explanation of the ANCOVA method to the Methods section.

Figure 6a shows raw data for BBB scores vs dorso-lateral white matter area. The data for the PcTx1-treated animals fall on the same general correlation as for the untreated animals, albeit the treated group had larger areas of preserved tissue compared to the untreated group. Initial analysis revealed the data were best described as a single dataset with the same slope and intercept. The figure emphasises the point that BBB performance appears to relate primarily to the amount of preserved white matter in both groups.
Similarly, Figure 6b shows raw data for horizontal ladder foot faults vs dorso-lateral white matter area. This figure emphasises that number of foot faults made on the horizontal ladder depends on the amount of preserved white matter.

**Minor Concerns:**

1. We apologise for omitting the references to the swimming test, these have now been added to the Methods section (Saunders *et al.*, 1998; Smith *et al.*, 2006; Magnuson *et al.*, 2009).

   The swimming test was included primarily to determine whether there was evidence of voluntary use of the hind limbs (when the limbs are not weight supporting) that would indicate some preservation of supra-spinal control. We have previously shown that opossums with complete spinal cord transections (no remaining supraspinal connections) do not move their hind limbs when swimming, but they do use them when climbing out of the tank and walking over a hard surface (Wheaton *et al.*, 2011).

   All animals in this study used their hind limbs in a brisk alternating pattern similar to uninjured controls.

   BBB subscores were not analysed.

2. The secondary method approved by our Animal Ethics and Welfare Committee was immediate opening of the chest cavity and transcardial perfuse fixation with paraformaldehyde. This information has been added to the Histological analysis section.

3. The 38 animals that were used for the tracer experiments have been added to the Methods section.

4. Amended as suggested.

5. We accept this recommendation which as an additional “less-subjective” assessment could be helpful to confirm treatment-induced improvements in BBB function.

**Figures**

Suggested changes made.

**Competing Interests:** No competing interests were disclosed.
